#VisualAbstract: Pertuzumab plus trastuzumab significantly improves survival in metastatic breast cancer
Click to read this study in JAMA Network Open.
Tag: metastatic breast cancer
Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to letrozole alone in patients with advanced breast cancer. ...
Pertuzumab has clinical benefits in metastatic breast cancer but is not cost-effective
1. The incremental cost-effectiveness ratio of the pertuzumab group was $436,679 per QALY gained. 2. Even if pertuzumab were free, ...
Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer
1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to ...
Clinicopathological heterogeneity in triple-negative breast cancers associated with variable prognosis and therapeutic outcomes
1. Heterogeneity in histological profile linked to improved overall survival, chemotherapy response, and clinical course despite triple-negative receptor status in ...
#VisualAbstract: Pyrotinib plus capecitabine improves progression-free survival in HER2⁺ metastatic breast cancer
Click to read the study in The Lancet Oncology.
#VisualAbstract: Everolimus plus leuprorelin and letrozole improves progression-free survival in HR⁺, HER2⁻ metastatic breast cancer patients with visceral metastases
Click to read the study in European Journal of Cancer
#VisualAbstract: Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer
Most estrogen receptor (ER)-positive breast cancers can be classified as luminal A or luminal B subtype. It has been estimated ...
Quick Take: Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in post-menopausal patients with luminal A or luminal B breast cancer
Most estrogen receptor (ER)-positive breast cancers can be classified as luminal A or luminal B subtype. It has been estimated ...